Cite
HARVARD Citation
Burgenske, D. et al. (2022). Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules. Neuro-oncology. 24 (3), pp. 384-395. [Online].